Chromadex Corp Stock OTC Bulletin Board
Stocks
CDXC
US1710771007
Biotechnology & Medical Research
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| Market Cap | 239M 207M 194M 177M 332M 22.9B 338M 2.28B 890M 11.47B 899M 880M 38.11B | P/E 2026 * |
22.5x | P/E 2027 * | 19.6x |
|---|---|---|---|---|---|
| Enterprise Value | 239M 207M 194M 177M 332M 22.9B 338M 2.28B 890M 11.47B 899M 880M 38.11B | EV / Sales 2026 * |
1.8x | EV / Sales 2027 * | 1.54x |
| Free-Float |
70.54% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Chromadex Corp
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Fried
CEO | Chief Executive Officer | 66 | 01/06/2018 |
Ozan Pamir
DFI | Director of Finance/CFO | 35 | 21/10/2024 |
Mona Rosene
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Jaksch
CHM | Chairman | 57 | 22/06/2018 |
Robert Fried
BRD | Director/Board Member | 66 | 09/07/2015 |
Steven Rubin
BRD | Director/Board Member | 65 | 27/03/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.78% | -1.68% | +1.48% | +15.31% | 48.42B | |
| +0.85% | -0.70% | +460.88% | +563.55% | 43.66B | |
| -2.40% | -0.23% | +8.13% | +71.41% | 39.51B | |
| -2.01% | -0.85% | +23.85% | +8.73% | 38.95B | |
| -0.50% | +0.85% | +20.60% | +49.65% | 32.61B | |
| +0.38% | -3.23% | - | - | 16.32B | |
| -0.59% | -2.06% | +26.35% | +118.09% | 16.15B | |
| +0.49% | +0.92% | +4.11% | +23.67% | 14.16B | |
| -0.43% | +4.70% | +78.74% | +33.31% | 13.37B | |
| Average | -0.67% | +0.49% | +78.02% | +110.46% | 29.24B | |
| Weighted average by Cap. | -0.91% | +0.59% | +95.83% | +132.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 133M 115M 108M 98.25M 185M 12.73B 188M 1.27B 495M 6.37B 500M 489M 21.18B | 155M 134M 126M 115M 216M 14.85B 219M 1.48B 577M 7.44B 583M 570M 24.71B |
| Net income | 10.88M 9.4M 8.83M 8.03M 15.11M 1.04B 15.35M 104M 40.47M 521M 40.87M 39.98M 1.73B | 12.82M 11.07M 10.41M 9.46M 17.79M 1.23B 18.09M 122M 47.67M 614M 48.14M 47.09M 2.04B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- NAGE Stock
- CDXC Stock
Select your edition
All financial news and data tailored to specific country editions
